Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861031 | 0.89 | MAPT (0.56) | MAPTTPSAB1ALDH1A1L3MBTL1HTT | |
| SCHEMBL877658 | 0.88 | ERCC1 (0.51) | ERCC1ERCC4TPSAB1ALDH1A1L3MBTL1 | |
| SCHEMBL24980145 | 0.85 | GAA (0.58) | ALDH1A1L3MBTL1HTTLMNAHPGD | |
| SCHEMBL12131750 | 0.79 | ERCC1 (0.70) | ERCC1ERCC4MAPTTPSAB1LMNA | |
| SCHEMBL14731447 | 0.78 | MEN1 (0.53) | MAPTTPSAB1ALDH1A1HTTLMNA | |
| SCHEMBL860819 | 0.76 | EPHX2 (0.43) | MAPTALDH1A1L3MBTL1HTTLMNA | |
| SCHEMBL24558042 | 0.74 | ERCC1 (0.64) | ERCC1ERCC4MAPTALDH1A1LMNA | |
| SCHEMBL22060073 | 0.74 | NPC1 (0.62) | ERCC1ERCC4ALDH1A1HTTLMNA | |
| SCHEMBL12134066 | 0.73 | ERCC1 (0.62) | ERCC1ERCC4MAPTALDH1A1 | |
| SCHEMBL22060015 | 0.73 | ERCC1 (0.62) | ERCC1ERCC4MAPTTPSAB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865130-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2013-02-28 | — | — | US | disclosed |
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
| US-7736624-B2 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | UNIV VANDERBILT (US) | 2010-06-15 | — | — | US | disclosed |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | VANDERBILT UNIVERSITY (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | ERCC1 3289/4885ERCC4 2832/4885MAPT 2607/4885 |
| US-20070292352-A1 | derivatives of non-steroidal anti-inflammatory drugs that exhibit selective binding to cyclooxygenase-2 (COX-2) and that comprise functional groups allowing them to be used for medical diagnosis and/or as therapeutic agents; tissue-targeted therapy | PTGES2, PTGS2, PTGER2 | ERCC1 4411/4885ERCC4 3819/4885MAPT 2603/4885 |
| US-20130052138-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | ERCC1 3289/4885ERCC4 2832/4885MAPT 2607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.